Why is information about the investigational product and potential randomization included in the consent discussion?

• A. To guarantee the participant will not withdraw.
• B. To focus solely on costs.
• C. To hide potential risks.
• D. To ensure the participant understands the investigational nature and, if applicable, possible random assignment.

Answer: (D)

The essential idea is that informed consent must give participants a clear understanding that the study medication is investigational and that they could be assigned to different groups by chance. Knowing the investigational status communicates that safety and efficacy are not fully established and that there may be unknown or uncertain risks. Being aware of randomization shows that treatment allocation isn’t controlled by the clinician and could mean receiving a placebo or a different dose or comparator, which can affect benefits and risks. This understanding helps the participant make a voluntary, informed decision about joining the trial. The other options don’t capture the purpose of consent: costs aren’t the primary focus, hiding risks is unethical, and guaranteeing no withdrawal is not true or relevant to what participants need to know to decide.